| Triple-Negative Breast Carcinoma studied in …STUDIED_INderived200 of 950show all (up to 200) |
|---|
| → studied in | NCT02883062Phase 2 · active not recruiting Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05891171Phase 1 · active not recruiting Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06505018NA · terminated Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment · condition mapped CURATED_BROADER · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06627712Phase 3 · recruiting SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06799065Phase 1/Phase 2 · recruiting First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07847398NA · not yet recruiting Emergence of Predictive Metabolomic Biomarkers of Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer. · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05007106Phase 2 · completed MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06586957Phase 1 · recruiting A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07698106Phase 1/Phase 2 · not yet recruiting Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02498613Phase 2 · active not recruiting A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors · condition mapped CURATED_BROADER · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02945579NA · recruiting Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy · condition mapped ONTOLOGY_EXACT · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04981119recruiting Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05528133Phase 2 · recruiting Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06393374Phase 3 · recruiting Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06841354Phase 3 · recruiting A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06966700Phase 3 · recruiting A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07066189NA · recruiting Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07419880Phase 2 · not yet recruiting Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07407920Phase 2 · recruiting Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial · condition mapped ONTOLOGY_EXACT · 950 trials mapped (453 active) | — | — | Early Stage Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07820228completed Survival Analysis of Early Triple Negative Breast Cancer (TNBC) Women Treated With Dose Dense Sequential Adjuvant Chemotherapy · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07339176Phase 1/Phase 2 · recruiting Intratumoral N17350 in Advanced Solid Tumors · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05422794Phase 1 · recruiting Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer · condition mapped CURATED_BROADER · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07528768Phase 2 · not yet recruiting HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry. · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07801508Phase 1 · recruiting A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05550415Phase 2 · recruiting The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05983432Phase 1 · recruiting Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04638751suspended ARGONAUT: Stool and Blood Sample Bank for Cancer Patients · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07340541Phase 2 · recruiting Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07705334Phase 1 · recruiting A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07828652not yet recruiting Real-world Treatment Outcomes and Safety of Neoadjuvant Pembrolizumab-containing Therapy in Patients With Triple-negative Breast Cancer: Korean Nationwide Multicenter Study (Pembro-Real World) · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07020117Phase 1 · recruiting A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07297667Phase 1 · recruiting GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06353997Phase 2 · recruiting Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04585750Phase 1/Phase 2 · recruiting The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05115474Phase 2 · recruiting Study of Screening Brain MRIs in Stage IV Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05809752Phase 1 · active not recruiting A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07513311NA · recruiting A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07743723Phase 1/Phase 2 · not yet recruiting A Study of IOV-5001 in Adults With Advanced Solid Tumors · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04191135Phase 2 · terminated Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06246968Phase 1 · recruiting A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07391956NA · recruiting Tier Palliative Care For Patients With Advanced Heart Failure or Cancer · condition mapped CURATED_BROADER · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04251533Phase 3 · terminated Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07638852Phase 2 · recruiting Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM. · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07652242Phase 1 · recruiting Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03606967Phase 2 · recruiting Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer · condition mapped CURATED_BROADER · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04030507NA · active not recruiting Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05570253Phase 2 · recruiting A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer · condition mapped CURATED_BROADER · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05633654Phase 3 · recruiting Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07679360Phase 3 · recruiting A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02208375Phase 1 · active not recruiting mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian · condition mapped ONTOLOGY_EXACT · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05192798Phase 2 · recruiting Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06400472Phase 1 · recruiting A Study of Sofe-M in Participants With Selected Advanced Solid Tumors · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06465069Phase 1 · recruiting A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07300475Phase 1 · not yet recruiting Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05846789Phase 2 · recruiting Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06245889Phase 2 · recruiting PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06337084Phase 1 · active not recruiting Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06617169Phase 1 · active not recruiting Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06635980Phase 2 · recruiting Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer · condition mapped ONTOLOGY_EXACT · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06649331Phase 2 · recruiting Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03893955Phase 1 · active not recruiting A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05868226Phase 1/Phase 2 · recruiting PRE-ISPY Phase I/II Oncology Platform Program · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03401385Phase 1 · active not recruiting First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07545122Phase 1 · recruiting A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02954874Phase 3 · active not recruiting Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05460273Phase 1/Phase 2 · active not recruiting A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05756166Phase 1/Phase 2 · terminated Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer · condition mapped CURATED_BROADER · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06460298Phase 1/Phase 2 · recruiting ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04427293Phase 1 · active not recruiting Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC) · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04677816Phase 2 · recruiting Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07029399Phase 1 · recruiting A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07630961Phase 1 · recruiting Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02993068NA · suspended Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) · condition mapped ONTOLOGY_EXACT · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06577987Phase 1 · active not recruiting Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07729956Phase 3 · not yet recruiting A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04) · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07786428Phase 2 · not yet recruiting Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07788222Phase 2 · not yet recruiting Sacituzumab Govitecan and Q901 in Advanced TNBC · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06084481Phase 1 · recruiting Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07743190Phase 2 · recruiting A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs) · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04360941Phase 1 · active not recruiting PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07321015Phase 2 · recruiting A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07623369Phase 1 · recruiting A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05269381Phase 1/Phase 2 · recruiting Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors · condition mapped CURATED_BROADER · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06027268Phase 2 · active not recruiting Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer · condition mapped CURATED_BROADER · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04803084suspended Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05827614Phase 1 · terminated Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07115043Phase 1/Phase 2 · recruiting A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07762703Phase 1/Phase 2 · not yet recruiting Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06685796Phase 2 · completed A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer · condition mapped CURATED_BROADER · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06910072Phase 2/Phase 3 · enrolling by invitation Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TNBC） · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07182149Phase 1 · recruiting A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07544056Phase 2/Phase 3 · recruiting A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer · condition mapped CURATED_BROADER · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04861077early Phase 1 · recruiting Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI) · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04895709Phase 1/Phase 2 · recruiting A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06358573Phase 2 · recruiting Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07341867Phase 1 · recruiting Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07768436Phase 2 · recruiting A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05985655Phase 1/Phase 2 · recruiting Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06399757Phase 1/Phase 2 · active not recruiting A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04768426Phase 2 · recruiting Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06610097NA · withdrawn TNBC Gut Microbiota During Neoadjuvant Treatment · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07272642Phase 1 · not yet recruiting A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors. · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07760844Phase 3 · not yet recruiting An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Everolimus in First to Third Line LAR Subtype TNBC · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05706129Phase 1/Phase 2 · recruiting A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05111561Phase 1 · recruiting Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07741968NA · recruiting A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer · condition mapped ONTOLOGY_EXACT · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07038369Phase 1 · active not recruiting A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07752550Phase 2 · not yet recruiting Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05581004Phase 1 · active not recruiting A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06176261Phase 2 · recruiting DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs · condition mapped CURATED_BROADER · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06586047early Phase 1 · recruiting Breast Cancer PSMA PET · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05309655NA · active not recruiting Cardiac Outcomes With Near-Complete Estrogen Deprivation · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05318469Phase 1/Phase 2 · recruiting Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer · condition mapped CURATED_BROADER · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05812807Phase 3 · recruiting Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab · condition mapped ONTOLOGY_EXACT · 950 trials mapped (453 active) | — | — | Early Stage Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07178730Phase 3 · not yet recruiting NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07552181Phase 2 · not yet recruiting Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03742102Phase 1/Phase 2 · active not recruiting A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05579366Phase 1/Phase 2 · recruiting Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07017673Phase 2 · recruiting Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07078604Phase 2 · recruiting A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer · condition mapped CURATED_BROADER · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07739485Phase 1/Phase 2 · recruiting Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07743632Phase 2 · not yet recruiting Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03077776NA · active not recruiting Tracking Triple-negative Breast Cancer Evolution Through Therapy · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06081244Phase 3 · recruiting NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07151586Phase 2 · not yet recruiting Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04052555Phase 1 · active not recruiting Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04345913Phase 1/Phase 2 · active not recruiting Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer · condition mapped CURATED_BROADER · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04491942Phase 1 · active not recruiting Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer · condition mapped ONTOLOGY_EXACT · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05673200Phase 1 · suspended Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer · condition mapped CURATED_BROADER · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06419621Phase 3 · active not recruiting PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06562192Phase 1 · recruiting Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07229417Phase 2 · recruiting A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Invasive Breast Lobular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06150664Phase 1 · recruiting A Phase 1 of CTX-8371 in Patients With Advanced Malignancies · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06347068Phase 1 · recruiting Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02445391Phase 3 · active not recruiting Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy · condition mapped ONTOLOGY_EXACT · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06604858Phase 2 · completed Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03915678Phase 2 · active not recruiting Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06078384Phase 2 · recruiting Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07458113Phase 2 · not yet recruiting Sac-TMT for Active TNBC Brain Metastases · condition mapped CURATED_BROADER · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05455658Phase 2 · active not recruiting STEMVAC in Patients With Early Stage Triple Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05714553Phase 1/Phase 2 · terminated NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06225505NA · recruiting Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06382142Phase 3 · active not recruiting A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02) · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06471205Phase 2 · recruiting A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06606730Phase 3 · recruiting Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07721259Phase 2 · not yet recruiting A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden · condition mapped ONTOLOGY_EXACT · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05208762Phase 1 · recruiting A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06157892Phase 2 · active not recruiting A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07318805Phase 1 · recruiting A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04348747Phase 2 · recruiting Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer · condition mapped CURATED_BROADER · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05552001Phase 3 · active not recruiting Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04758780Phase 2 · completed Imaging Performance Assessment of 89Zi-girentuximab (89Zr-TLX250) PET in Metastatic Triple Negative Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07714382completed Survival Outcomes of Residual Disease in Triple-Negative Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04230109Phase 2 · recruiting Sacituzumab Govitecan In TNBC · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05078047Phase 3 · active not recruiting Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07064018Phase 1/Phase 2 · recruiting Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02276443NA · active not recruiting Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative · condition mapped ONTOLOGY_EXACT · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02411656Phase 2 · active not recruiting Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy · condition mapped ONTOLOGY_EXACT · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07258563NA · recruiting The TASTY-steering Study · condition mapped CURATED_BROADER · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07705438recruiting Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01116648Phase 1/Phase 2 · active not recruiting Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04443348Phase 2 · active not recruiting Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05451849Phase 1/Phase 2 · terminated A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06976944Phase 2 · recruiting Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer · condition mapped CURATED_BROADER · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07137416Phase 1 · recruiting Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer · condition mapped CURATED_BROADER · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05101096Phase 1/Phase 2 · active not recruiting Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors · condition mapped CURATED_BROADER · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07570524recruiting Predicting Response to Immunochemotherapy in Early Triple Negative Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07681297Phase 1/Phase 2 · not yet recruiting Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04331067Phase 1/Phase 2 · terminated Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04216472Phase 2 · terminated Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations · condition mapped ONTOLOGY_EXACT · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07011654Phase 1/Phase 2 · recruiting Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC) · condition mapped CURATED_BROADER · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03330847Phase 2 · active not recruiting To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. · condition mapped CURATED_BROADER · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02957968Phase 2 · active not recruiting Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca · condition mapped ONTOLOGY_EXACT · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05967533Phase 1 · suspended The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors · condition mapped CURATED_BROADER · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03012100Phase 2 · active not recruiting Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06449222Phase 2 · active not recruiting Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00861705Phase 2 · completed Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery · condition mapped ONTOLOGY_EXACT · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05377996Phase 1/Phase 2 · recruiting A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05677802NA · recruiting Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07327489recruiting Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05) · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07672431NA · not yet recruiting Study of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer After Progression · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01750073Phase 2 · completed Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer · condition mapped ONTOLOGY_EXACT · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01805076Phase 3 · completed MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05082259Phase 1 · active not recruiting ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07136493NA · withdrawn Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer · condition mapped ONTOLOGY_EXACT · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07669610Phase 3 · not yet recruiting An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02750358Phase 2 · active not recruiting Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05770531Phase 2 · recruiting Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy · condition mapped CURATED_BROADER · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07217990Phase 1/Phase 2 · not yet recruiting Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05005403Phase 1 · recruiting Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07046923Phase 1 · recruiting A Study of LY4175408 in Participants With Advanced Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07581314Phase 1/Phase 2 · not yet recruiting Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07662252not yet recruiting Circulating Tumor DNA Dynamics to Optimize Neoadjuvant Therapy in HER2-Positive and Triple-Negative Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06545331Phase 1 · recruiting Study of XB010 in Subjects With Solid Tumors · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07503808Phase 1 · recruiting A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03213041Phase 2 · completed Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer · condition mapped ONTOLOGY_EXACT · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03362060Phase 1 · active not recruiting PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03945721Phase 1 · active not recruiting A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04837209Phase 2 · active not recruiting Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07092254active not recruiting Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer · condition mapped ALIAS · 950 trials mapped (453 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |